LEXARIA BIOSCIENCE CORP. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
LEXARIA BIOSCIENCE CORP. (LEXX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $0.65 per share for the 9-month period ending 2026-05-31, per its 10-Q filed 2026-07-13.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-07-13
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-11-30 was $1.15, a 43.63% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-11-30 was $2.04, a 67.26% decline year-over-year.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-05-31 was $3.39.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-11-30 was $6.23.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $4.21, a 22.18% decline from fiscal 2021.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $5.41, a 53.60% decline from fiscal 2020.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $11.66, a 1066.00% increase from fiscal 2019.
- LEXARIA BIOSCIENCE CORP. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2019 was $1.00, a 32.89% decline from fiscal 2018.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 0 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 1 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-05-31 | $0.65 10-Q · filed 2026-07-13 | |||||||
| 2025-08-31 | $1.41 10-Q · filed 2026-07-13 | |||||||
| 2024-05-31 | $1.24 10-Q · filed 2024-07-12 | |||||||
| 2024-02-29 | $1.15 10-Q · filed 2024-04-09 | |||||||
| 2023-11-30 | $1.15 10-Q · filed 2024-01-12 | |||||||
| 2023-10-27 | $1.15 10-K · filed 2023-11-20 | |||||||
| 2023-10-26 | $1.15 10-Q · filed 2024-01-12 | |||||||
| 2023-08-31 | $1.75 10-Q · filed 2024-07-12 | |||||||
| 2023-05-31 | $2.11 10-Q · filed 2023-07-14 | |||||||
| 2023-05-11 | $0.95 10-Q · filed 2024-01-12 | |||||||
| 2023-02-28 | $2.11 10-Q · filed 2023-04-14 | |||||||
| 2022-11-30 | $2.04 10-Q/A · filed 2023-01-18 | |||||||
| 2022-08-31 | $4.21 10-K · filed 2023-11-20 | |||||||
| 2022-05-31 | $3.39 10-Q · filed 2022-07-14 | $6.23 10-Q · filed 2022-07-14 | ||||||
| 2022-02-28 | $6.23 10-Q · filed 2022-04-11 | |||||||
| 2021-11-30 | $6.23 10-Q · filed 2022-01-14 | |||||||
| 2021-08-31 | $5.41 10-K · filed 2022-11-28 | |||||||
| 2021-05-31 | $5.22 10-Q · filed 2021-07-15 | |||||||
| 2021-02-28 | $4.80 10-Q · filed 2021-04-14 | |||||||
| 2020-08-31 | $11.66 10-K · filed 2021-11-29 | $0.39 10-K · filed 2020-10-15 | ||||||
| 2020-05-31 | $0.32 10-Q · filed 2020-06-29 | $0.39 10-Q · filed 2020-06-29 | ||||||
| 2020-02-29 | $0.54 10-Q · filed 2020-04-03 | |||||||
| 2019-11-30 | $11.66 10-Q · filed 2021-01-14 | |||||||
| 2019-08-31 | $1.00 10-K · filed 2020-10-15 | |||||||
| 2019-02-28 | $0.83 10-Q · filed 2019-04-15 | |||||||
| 2018-11-30 | $1.27 10-Q · filed 2019-01-11 | |||||||
| 2018-08-31 | $1.49 10-K · filed 2019-11-14 | |||||||
| 2018-05-31 | $1.53 10-Q · filed 2018-07-13 | $0.83 10-Q · filed 2019-07-08 | $1.46 10-Q · filed 2018-07-13 | |||||
| 2018-02-28 | $0.83 10-Q · filed 2018-04-12 | |||||||
| 2017-12-31 | $0.83 10-Q · filed 2018-07-13 | |||||||
| 2017-08-31 | $0.14 10-K · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |